Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

Posted in Biotech by Medtech[y] Staff

September 30, 2019 • 2 min read

​Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, today announced the completion of its merger with Histogenics Corporation (previously NASDAQ: HSGX), and the change of the combined company’s name to “Ocugen, Inc.” Ocuge...

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Posted in Medical Device by Medtech[y] Staff

September 30, 2019 • 2 min read

​Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive one-year results of its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial, successfully achieving both primary and secondary endpoints. Marianne Brodmann, M.D., Head of the Clinical Division of Angiology...

Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

Posted in Biotech by Medtech[y] Staff

September 30, 2019 • 2 min read

​Vertex Pharma Incorporated (NASDAQ:VRTX) and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery...

AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA (tivozanib) in Combination with IMFINZI (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

Posted in Biotech by Medtech[y] Staff

September 30, 2019 • 2 min read

AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI)...

Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

Posted in Biotech by Medtech[y] Staff

September 27, 2019 • 2 min read

​Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD)...

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

Posted in Biotech by Medtech[y] Staff

September 26, 2019 • 2 min read

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio®) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) ...